Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,089 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01982955 | Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | completed | Phase 1 / Phase 2 | 88 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 7 | Nov 8, 2022 | clinicaltrials |
| NCT05590572 | A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | not yet recruiting | Phase 1 / Phase 2 | 148 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Oct 21, 2022 |
| clinicaltrials |
| NCT04509557 | [177Lu]Ludotadipep Treatment in Patients With Metastatic Castration-resistant Prostate Cancer. | completed | Phase 1 | 30 | FutureChemINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02866006 | Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer | completed | Phase 1 / Phase 2 | 32 | Cellid Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02588105 | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer(AToM) | completed | Phase 1 | 84 | AstraZenecaINDUSTRY | 4 | Sep 19, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT01988493 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 117 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Aug 24, 2022 | clinicaltrials |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02711969 | A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | completed | Phase 1 | 6 | Bukwang PharmaceuticalINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03517956 | Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors(ROCOCO) | completed | Phase 1 | 16 | BayerINDUSTRY | 6 | Jul 14, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT05439993 | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma | unknown | Phase 1 / Phase 2 | 42 | Hallym University Medical CenterOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03102320 | Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors(ARCS-Multi) | completed | Phase 1 | 173 | BayerINDUSTRY | 12 | Jun 30, 2022 | clinicaltrials |
| NCT04460456 | A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors | unknown | Phase 1 | 58 | Silverback TherapeuticsINDUSTRY | 3 | Jun 30, 2022 | clinicaltrials |
| NCT02648724 | Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 57 | Symphogen A/SINDUSTRY | 6 | Jun 22, 2022 | clinicaltrials |
| NCT02508532 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | completed | Phase 1 | 250 | Blueprint Medicines CorporationINDUSTRY | 10 | Jun 21, 2022 | clinicaltrials |
| NCT02630199 | Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer | completed | Phase 1 | 65 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04258072 | Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma. | unknown | Phase 1 | 24 | Samsung Medical CenterOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03052933 | Copanlisib and Gemcitabine in Relapsed/Refractory PTCL | completed | Phase 1 / Phase 2 | 28 | Chonnam National University HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT04335604 | A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors | completed | Phase 1 | 62 | Onconic Therapeutics Inc.INDUSTRY | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT03913234 | Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 95 | Yonsei UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT02343120 | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 385 | BeiGeneINDUSTRY | 6 | Apr 28, 2022 | clinicaltrials |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 140 | Polaris GroupINDUSTRY | 6 | Apr 25, 2022 | clinicaltrials |
| NCT05068193 | A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers | completed | Phase 1 | 57 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 12 | Elevar TherapeuticsINDUSTRY | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02088112 | MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC). | completed | Phase 1 | 56 | MedImmune LLCINDUSTRY | 3 | Apr 4, 2022 | clinicaltrials |
| NCT02410512 | A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 610 | Genentech, Inc.INDUSTRY | 7 | Apr 1, 2022 | clinicaltrials |
| NCT03937895 | Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 40 | SMT bio Co., Ltd.INDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04669587 | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)(ENZENO) | unknown | Phase 1 / Phase 2 | 106 | EnhancedBio USA Inc.OTHER | 2 | Mar 22, 2022 | clinicaltrials |
| NCT04835584 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 109 | Kartos Therapeutics, Inc.INDUSTRY | 8 | Mar 21, 2022 | clinicaltrials |
| NCT04065087 | Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) | unknown | Phase 1 | 20 | Seoul National University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03454620 | A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy | completed | Phase 1 / Phase 2 | 53 | Green Cross CorporationINDUSTRY | 1 | Mar 3, 2022 | clinicaltrials |
| NCT02299505 | Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 306 | Novartis PharmaceuticalsINDUSTRY | 24 | Feb 9, 2022 | clinicaltrials |
| NCT03696771 | Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT03281824 | Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | completed | Phase 1 | 27 | Alteogen, Inc.INDUSTRY | 1 | Jan 18, 2022 | clinicaltrials |
| NCT01332266 | E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 95 | Eisai Inc.INDUSTRY | 4 | Jan 3, 2022 | clinicaltrials |
| NCT01772004 | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | completed | Phase 1 | 1,756 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 9 | Dec 20, 2021 | clinicaltrials |
| NCT02407990 | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors | completed | Phase 1 | 451 | BeiGeneINDUSTRY | 5 | Nov 17, 2021 | clinicaltrials |
| NCT03364049 | Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 4 | Nov 15, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 8, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials